<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382586</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-219</org_study_id>
    <nct_id>NCT04382586</nct_id>
  </id_info>
  <brief_title>Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate if the addition of zanubrutinib to
      supportive care increases the respiratory failure-free survival rate at Day 28 in
      participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory failure-free survival rate at day 28</measure>
    <time_frame>28 Days</time_frame>
    <description>Respiratory failure-free survival rate 28 is defined as the proportion of patients who have not had respiratory failure nor died &lt;= 28 days from randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median reduction in days spent on supplemental oxygen</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants experiencing respiratory failure or death</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation-free survival</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on mechanical ventilation</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2:FiO2 and/or oxygenation index</measure>
    <time_frame>Up to 28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>This scale evaluates the safety and efficacy of investigational therapeutic agents in combination with care for the treatment of hospitalized participants suffering from COVID-19 infections on a scale of scores from 0 to 8, with higher scores indicating higher level of severity of the disease. (0 = No clinical or virological evidence of disease, and 8 = Death)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>COVID-19 Pulmonary Complications</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Zanubrutinib + Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants not requiring mechanical ventilation (Cohort 1) will receive zanubrutinib plus supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo + Supportive Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants not requiring mechanical ventilation (Cohort 1) will receive placebo plus supportive care alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Zanubrutinib+Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have been on mechanical ventilation for ≤ 24 hours (Cohort 2) will receive zanubrutinib plus supportive care alone for respiratory distress due to COVID-19 infection for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>320 mg (4 x 80 mg) capsules administered orally once daily.</description>
    <arm_group_label>Cohort 1: Zanubrutinib + Supportive Care</arm_group_label>
    <arm_group_label>Cohort 2: Zanubrutinib+Supportive Care</arm_group_label>
    <other_name>BGB-3111</other_name>
    <other_name>Brukinsa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supportive Care</intervention_name>
    <description>Supportive care treatment is selected and administered as deemed appropriate by the study investigator.</description>
    <arm_group_label>Cohort 1: Placebo + Supportive Care</arm_group_label>
    <arm_group_label>Cohort 1: Zanubrutinib + Supportive Care</arm_group_label>
    <arm_group_label>Cohort 2: Zanubrutinib+Supportive Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match zanubrutinib</description>
    <arm_group_label>Cohort 1: Placebo + Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Hospitalization for COVID-19 infection

          2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by
             polymerase chain reaction (PCR)

          3. Cohort 1: Participant requires supplemental oxygen for pulmonary distress related to
             COVID-19 infection, and has been on supplemental oxygen for no more than 48 hours.
             Cohort 2: Participants will have been on mechanical ventilation for ≤ 24 hours from
             the time of screening

          4. Radiographic evidence of pulmonary infiltrates

        Key Exclusion Criteria:

          1. Participant is on mechanical ventilation for &gt; 24 hours

          2. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, symptomatic inflammatory bowel disease or
             ulcerative colitis, or partial or complete bowel obstruction

          3. On a BTK inhibitor

          4. Planned or concurrent use of tocilizumab

          5. Participants with cancer

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Zimmerman, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olive View - UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Heath Research Institute/ MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John D. Archbold Memorial Hospital</name>
      <address>
        <city>Thomasville</city>
        <state>Georgia</state>
        <zip>31792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SIU School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham And Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System, Inc. / Chilton Medical Center</name>
      <address>
        <city>Pompton Plains</city>
        <state>New Jersey</state>
        <zip>07444</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Covenant Health System</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Dor de Pesquisa E Ensino</name>
      <address>
        <city>São Paulo</city>
        <zip>04502</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corona Virus</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

